Peptide-functionalized nanoparticles for the selective induction of apoptosis in target cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 32(3–4), 723–761 (2013).
  Medline CASGoogle Scholar
• 2 Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52–79 (2015).
  Medline CASGoogle Scholar
• 3 Lu DY, Lu TR, Che JY, Wu HY. Individualized cancer therapy. Innovations Pharm. Pharmacother. 2(4), 458–469 (2014).
  CASGoogle Scholar
• 4 Haslam D. Weight management in obesity – past and present. Int. J. Clin. Pract. 70(3), 206–217 (2016).
  Medline CASGoogle Scholar
• 5 Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann. NY Acad. Sci. 1311, 1–13 (2014).
  Medline CASGoogle Scholar
• 6 Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther. Adv. Chronic Dis. 5(3), 135–148 (2014).
  Medline CASGoogle Scholar
• 7 Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J. Diabetes 2(2), 19–23 (2011).
  MedlineGoogle Scholar
• 8 Wu X, Baig A, Kasymjanova G et al. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12), e924 (2016).
  MedlineGoogle Scholar
• 9 Cheung BMY, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther. Adv. Drug Saf. 4(4), 171–181 (2013).
  MedlineGoogle Scholar
• 10 Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945), 766–781 (2014).
  MedlineGoogle Scholar
• 11 Zheng H, Tumin D, Qian Z. Obesity and mortality risk: new findings from body mass index trajectories. Am. J. Epidemiol. 178(11), 1591–1599 (2013).
  MedlineGoogle Scholar
• 12 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
  MedlineGoogle Scholar
• 13 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013).
  MedlineGoogle Scholar
• 14 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 15 Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br. J. Radiol. 88(1054), 20150207 (2015).
  Medline CASGoogle Scholar
• 16 Chen WH, Chen JX, Cheng H et al. A new anti-cancer strategy of damaging mitochondria by pro-apoptotic peptide functionalized gold nanoparticles. Chem. Commun. 49, 6403 (2013).
  Medline CASGoogle Scholar
• 17 Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther. Deliv. 3(4), 457–478 (2012).
  Medline CASGoogle Scholar
• 18 Theek B, Rizzo LY, Ehling J, Kiessling F, Lammers T. The theranostic path to personalized nanomedicine. Clin. Transl. Imaging 2(1), 66–76 (2014).
  MedlineGoogle Scholar
• 19 Zhang X. Gold nanoparticles: recent advances in the biomedical applications. Cell Biochem. Biophys. 72, 771–775 (2015).
  Medline CASGoogle Scholar
• 20 Zdrojewicz Z, Waracki M, Bugaj B, Pypno D, Cabała K. Medical applications of nanotechnology. Postepy Hig. Med. Dosw. 69, 1196–1204 (2015).
  Google Scholar
• 21 Dreaden EC, El-Sayed MA. Detecting and destroying cancer cells in more than one way with noble metals and different confinement properties on the nanoscale. Acc. Chem. Res. 45(11), 1854–1865 (2012).
  Medline CASGoogle Scholar
• 22 Pramanik AK, Siddikuzzaman, Palanimuthu D, Somasundaram K, Samuelson AG. Biotin decorated gold nanoparticles for targeted delivery of a smart-linked anticancer active copper complex: in vitro and in vivo studies. Bioconjug. Chem. 27(12), 2874–2885 (2016).
  Medline CASGoogle Scholar
• 23 Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10(3), 831–847 (2013).
  Medline CASGoogle Scholar
• 24 Daraee H, Eatemadi A, Abbasi E, Fekri AS, Kouhi M, Akbarzadeh A. Application of gold nanoparticles in biomedical and drug delivery. Artif. Cells Nanomed. Biotechnol. 44(1), 410–422 (2016).
  Medline CASGoogle Scholar
• 25 Karmani L, Bouchat V, Bouzin C et al. (89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy. Nanomedicine 9(13), 1923–1937 (2014).
  CASGoogle Scholar
• 26 Xiao Z, Levy-Nissenbaum E, Alexis F et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 6(1), 696–704 (2012).
  Medline CASGoogle Scholar
• 27 Chen WH, Luo GF, Xu XD et al. Cancer-targeted functional gold nanoparticles for apoptosis induction and real-time imaging based on FRET. Nanoscale 6(16), 9531–9535 (2014).
  Medline CASGoogle Scholar
• 28 Meyers JD, Cheng Y, Broome AM et al. Peptide-targeted gold nanoparticles for photodynamic therapy of brain cancer. Part. Part. Syst. Charact. 32(4), 448–457 (2015).
  Medline CASGoogle Scholar
• 29 Cocco E, Deng Y, Shapiro EM et al. Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells. Mol. Cancer Ther. 16(2), 323–333 (2017).
  Medline CASGoogle Scholar
• 30 Beh CY, How CW, Foo JB, Foong JN, Selvarajah GT, Rasedee A. Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers. Drug Des. Dev. Ther. 11, 771–782 (2017).
  Medline CASGoogle Scholar
• 31 Badr G, Al-Sadoon MK, Raba DM. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models. Free Radic. Biol. Med. 65, 175–89 (2013).
  Medline CASGoogle Scholar
• 32 Hossen MN, Kajimoto K, Akita H, Hyodo M, Ishitsuka T, Harashima H. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. J. Control. Release 147(2), 261–268 (2010). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 33 Thovhogi N, Sibuyi N, Martin O, Meyer M, Madiehe A. Targeted delivery of peptide-functionalized gold nanoparticles to white adipose tissues of obese rats. J. Nanopart. Res. 17, 112 (2015). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Google Scholar
• 34 Wang F, Wang YC, Dou S et al. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 5(5), 3679–3692 (2011).
  Medline CASGoogle Scholar
• 35 Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16(24), 6139–6149 (2010).
  Medline CASGoogle Scholar
• 36 Clinical Trials database: NCT00356980. https://clinicaltrials.gov/ct2/show/NCT00356980.
  Google Scholar
• 37 Clinical Trials database: NCT00436410. https://clinicaltrials.gov/ct2/show/NCT00436410.
  Google Scholar
• 38 Clinical Trials database: NCT00848042. https://clinicaltrials.gov/ct2/show/NCT00848042.
  Google Scholar
• 39 Kumar A, Ma H, Zhang X et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 33(4), 1180–1189 (2012). • Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 40 Libutti SK, Paciotti GF, Myer L et al. Results of a completed Phase I clinical trial of CYT-6091: a pegylated colloidal gold-TNF. Nanomedicine 27, 3586 (2009).
  Google Scholar
• 41 Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10, 625–632 (2004). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 42 O'Dwyer D, Ralton LD, O'Shea A, Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS ONE 6(11), e27718 (2011).
  MedlineGoogle Scholar
• 43 Zhong N, Cui Y, Zhou X, Li T, Han J. Identification of prohibitin 1 as a potential prognostic biomarker in human pancreatic carcinoma using modified aqueous two-phase partition system combined with 2D-MALDI-TOF-TOF-MS/MS. Tumour Biol. 36(2), 1221–1231 (2015).
  Medline CASGoogle Scholar
• 44 Gamble SC, Odontiadis M, Waxman J et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 23, 2996–3004 (2004).
  Medline CASGoogle Scholar
• 45 Mishra S, Murphy LC, Nyomba BL, Murphy GLJ. Prohibitin: a potential target for new therapeutics. Trends Mol. Med. 11(4), 192–197 (2005).
  Medline CASGoogle Scholar
• 46 Nijtmans LGJ, de Jong L, Sanz MA et al. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 19(11), 2444–2451 (2000).
  Medline CASGoogle Scholar
• 47 Artal-Sanz M, Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol. Metab. 8, 394–401 (2009).
  Google Scholar
• 48 Merkwirth C, Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim. Biophys. Acta 1793(1), 27–32 (2009).
  Medline CASGoogle Scholar
• 49 Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H. Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery. J. Control. Release 163, 101–110 (2012). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 50 Kwon MK, Nam JO, Park RW et al. Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3. Mol. Cancer Ther. 7(6), 1514–1522 (2008). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 51 Ellerby HM, Arap W, Ellerby LM et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5(9), 1032–1038 (1999). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 52 Javadpour MM, Juban MM, Lo WJ et al. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 39, 3107–3113 (1996). • Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar
• 53 Barnhart KF, Christianson DR, Hanley PW et al. A Peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med. 3, 108–112 (2011). •• Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Google Scholar
• 54 Sosibo NM, Keter FK, Skepu A, Tshikhudo RT. Facile attachment of tat peptide on gold monolayer protected clusters: synthesis and characterization. Nanomaterials 5(3), 1211–1222 (2015).
  Medline CASGoogle Scholar
• 55 Meyer M, Essack M, Kanyanda S, Rees J. A low-cost flow cytometric assay for the detection and quantification of apoptosis using an anionic halogenated fluorescein dye. Biotechniques 45(3), 317–320 (2008).
  Medline CASGoogle Scholar
• 56 Clogston JD, Patri AK. Zeta potential measurement. Methods Mol. Biol. 697, 63–70 (2011).
  Medline CASGoogle Scholar
• 57 Sharma A, Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl Acad. Sci. USA 101(50), 17492–17497 (2004).
  Medline CASGoogle Scholar
• 58 Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol. Cell. Biol. 26(11), 4161–4171 (2006).
  Medline CASGoogle Scholar
• 59 Rastogi S, Joshi B, Fusaro G, Chellappan S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J. Biol. Chem. 281(5), 2951–2959 (2006).
  Medline CASGoogle Scholar
• 60 Shao X, Schnau P, Qian W, Wang X. Quantitatively understanding cellular uptake of gold nanoparticles via radioactivity analysis. J. Nanosci. Nanotechnol. 15(5), 3834–3838 (2015).
  Medline CASGoogle Scholar
• 61 Zarska M, Novotny F, Havel F et al. Two-step mechanism of cellular uptake of cationic gold nanoparticles modified by (16 mercaptohexadecyl)trimethylammonium bromide. Bioconjug. Chem. 27(10), 2558–2574 (2016).
  Medline CASGoogle Scholar
• 62 Perreault A, Richter S, Bergman C, Wuest M, Wuest F. Targeting phosphatidylserine with a 64cu-labeled peptide for molecular imaging of apoptosis. Mol. Pharm. 13(10), 3564–3577 (2016).
  Medline CASGoogle Scholar
• 63 Loreto C, La Rocca G, Anzalone R et al. The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease. Biomed. Res. Int. 2014, 616149 (2014).
  MedlineGoogle Scholar
• 64 Chen F, Lu X, Yang X et al. Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology. Int. J. Oncol. 37(2), 355–365 (2010).
  Medline CASGoogle Scholar
• 65 Kimura Y, Matsumoto H, Oosawa M et al. Relationship between visceral fat and development of colorectal neoplasms using computed tomographic colonography and adipocytokine levels. Nihon Shokakibyo Gakkai Zasshi 111(11), 2121–2130 (2014).
  MedlineGoogle Scholar
• 66 Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Chem. Immunol. Allergy 99, 170–179 (2014).
  Medline CASGoogle Scholar
• 67 Daquinag AC, Zhang Y, Kolonin MG. Vascular targeting of adipose tissue as an anti-obesity approach. Trends Pharmacol. Sci. 32(5), 300–307 (2011). • Proof that vascular-targeted nanotherapies could be a feasible approach for the treatment of chronic diseases.
  Medline CASGoogle Scholar